The Readout Loud
397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
On this week’s episode of the Readout LOUD: a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in lymphoma.
Your favorite biotech podcasting crew is back to full strength this week, and we’re bringing you two newsy guest interviews. First, we’ll talk with Allogene Therapeutics Chief Medical Officer Zach Roberts about new study results that bolster the company’s efforts to develop an off-the-shelf CAR-T therapy for B-cell lymphoma, a type of blood cancer.Then, we’ll dive into the biggest news of the week: Revolution Medicines and the stunning survival benefit reported for its experimental drug in a Phase 3 pancreatic cancer study. Paul Oberstein, a pancreatic cancer expert from NYU Langone, will join us to discuss the Revolution Medicines data and what it means for pancreatic cancer patients.